Exp Clin Endocrinol Diabetes 2007; 115(7): 468-470
DOI: 10.1055/s-2007-981661
Case Report

© J. A. Barth Verlag in Georg Thieme Verlag KG · Stuttgart · New York

The Association of Neurofibromatosis, Bilateral Pheochromocytoma and Primary Hyperparathyroidism

A. E. Altinova 1 , F. Toruner 1 , A. R. Cimen 2 , A. Karakoc 1 , T. Atasever 3 , I. Yetkin 1 , G. Ayvaz 1 , N. Cakir 1 , M. Arslan 1
  • 1Department of Endocrinology and Metabolism, Gazi University Faculty of Medicine, Ankara, Turkey
  • 2Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Turkey
  • 3Department of Nuclear Medicine, Gazi University Faculty of Medicine, Ankara, Turkey
Further Information

Publication History

received 1.10.2006 first decision 7.11.2006

accepted 12.12.2006

Publication Date:
23 July 2007 (online)


Neurofibromatosis (NF) is a hereditary disease and carries increased risk of both benign and malignant tumor development. Pheochromocytoma or hyperparathyroidism have been reported to be associated with NF type 1 (NF1). However, the coexistance of pheochromocytoma and parathyroid adenoma in a patient with NF1 is very rare. We report a case of a 37-year-old male with NF1, bilateral pheochromocytoma and parathyroid adenoma. This association sould be kept in mind in patients with NF1 in initial evaluation as well as during follow-up.


  • 1 Abdel-Wanis ME, Kawahara N, Tomita K. The association of neurofibromatosis 1 and spinal deformity with primary hyperparathyroidism and osteomalacia: might melatonin have a role?.  J Orthop Sci. 2001;  6 193-198
  • 2 Al-Wahhabi B. Parathyroid adenoma and bilateral pheochromocytoma in a patient with neurofibromatosis.  Ann Saudi Med. 2005;  25 255-257
  • 3 Benn DE, Dwight T, Richardson AL, Delbridge L, Bambach CP, Stowasser M, Gordon RD, Marsh DJ, Robinson BG. Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p.  Cancer Res. 2000;  60 7048-7051
  • 4 Chakrabarti S, Murugesan A, Arida EJ. The association of neurofibromatosis and hyperparathyroidism.  Am J Surg. 1979;  137 417-420
  • 5 Daly D, Kaye M, Estrada RL. Neurofibromatosis and hyperparathyroidism-a new syndrome?.  Can Med Assoc J. 1970;  103 258-259
  • 6 Freimanis MG, Rodgers RW, Samaan NA. Neurofibromatosis and primary hyperparathyroidism.  South Med J. 1984;  77 794-795
  • 7 Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients.  Am J Med Genet. 1997;  70 138-143
  • 8 Gimm O. Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx.  Fam Cancer. 2005;  4 17-23
  • 9 Giorgetti PL, Pizzocari P, De Monti M, Rampoldi V, Rignano A, Vandone PL, Miani S. Association of pheochromocytoma and phakomatosis. Apropos of a clinical case.  Minerva Chir. 1991;  46 479-488
  • 10 Goldberg Y, Dibbern K, Klein J, Riccardi VM, Graham Jr JM. Neurofibromatosis type 1-an update and review for the primary pediatrician.  Clin Pediatr (Phila). 1996;  35 545-561
  • 11 Hernandez FC, Sanchez M, Alvarez A, Diaz J, Pascual R, Perez M, Tovar I, Martinez P. A five-year report on experience in the detection of pheochromocytoma.  Clin Biochem. 2000;  33 649-655
  • 12 Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla.  Horm Metab Res. 2005;  37 717-721
  • 13 Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, Peltonen J. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body.  Osteoporos Int. 2005;  16 928-936
  • 14 Learoyd DL, Marsh DJ, Richardson AL, Twigg SM, Delbridge L, Robinson BG. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2.  Arch Surg. 1997;  132 1022-1025
  • 15 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma.  Lancet. 2005;  366 665-675
  • 16 Moiton MP, Bijou F, Vargas F, Valentino R, Gruson D, Hilbert G, Benissan G, Cardinaud JP. Association of type 1 neurofibromatosis and primary hyperparathyroidism.  Presse Med. 2002;  31 1604-1605
  • 17 Opocher G, Conton P, Schiavi F, Macino B, Mantero F. Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1.  Fam Cancer. 2005;  4 13-16
  • 18 Patocs A, Karadi E, Toth M, Varga I, Szucs N, Balogh K, Majnik J, Glaz E, Racz K. Clinical and biochemical features of sporadic and hereditary phaeochromocytomas: an analysis of 41 cases investigated in a single endocrine centre.  Eur J Cancer Prev. 2004;  13 403-409
  • 19 Pawlu C, Bausch B, Reisch N, Neumann HP. Genetic testing for pheochromocytoma-associated syndromes.  F Ann Endocrinol. 2005;  66 178-185
  • 20 Rasmussen SA, Friedman JM. NF1 gene and neurofibromatosis.  Am J Epidemiol. 2000;  151 33-40
  • 21 Schimke RN, Hartmann WH, Prout TE, Rimoin DL. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas. A possible regulatory defect in the differentiation of chromaffin tissue.  N Engl J Med. 1968;  279 1-7
  • 22 Segni M, Massa R, Bonifacio V, Tartaglia F, Pucarelli I, Marzullo A, Pasquino AM. Thyroid C-cell hyperplasia in an adolescent with neurofibromatosis type 1.  Horm Res. 2001;  56 63-66
  • 23 Syed Z, Khan A. Skeletal effects of primary hyperparathyroidism.  Endocr Pract. 2000;  6 385-388
  • 24 Vogelzang PJ, Oates E, Bankoff MS. Parathyroid adenoma associated with neurofibromatosis: correlative scintigraphic and magnetic resonance imaging.  Clin Nucl Med. 1989;  14 168-170
  • 25 Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM. Von Recklinghausen's disease and pheochromocytomas.  J Urol. 1999;  62 582-586
  • 26 Yohay K. Neurofibromatosis types 1 and 2.  Neurologist. 2006;  12 86-93


Dr. A. E. Altinova

Ahmet Rasim Sok. 41/6

06550 Çankaya



Phone: +90/312/202 58 33

Fax: +90/312/215 42 04

Email: alevaltinova@yahoo.com